StemoniX

14 articles about StemoniX

• Cancer Genetics and StemoniX Announce Merger Closing

  3/31/2021

  Cancer Genetics, Inc., an emerging leader in novel drug discovery techniques, and StemoniX, Inc., a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, announced their recently approved transaction has closed, and in connection with the merger, Cancer Genetics, Inc. was renamed Vyant Bio, Inc. effective March 30, 2021.

• Cancer Genetics and StemoniX Announce Joint Proof-of-Concept Program

  9/3/2020

  Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, and StemoniX, Inc., a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, today announced a joint proof-of-concept program. StemoniX and vivo Pharm ® , a subsidiary of Cancer Genetics, recently launched a joint proof-of-concept p

• Cancer Genetics and StemoniX Sign Definitive Agreement to Merge

  8/24/2020

  Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), and StemoniX, Inc., today announced the entry into a definitive merger agreement. Cancer Genetics is a leader in drug discovery and preclinical oncology and immuno-oncology services.

• StemoniX's microBrain® to be Featured in Podium Presentation at SLAS 2020 International Conference & Exhibition

  1/27/2020

  StemoniX, a biotech company revolutionizing how new medicines are discovered, announced today that its Director of Applications, Oivin Guichert, Ph.D., will deliver a podium presentation highlighting the company's microBrain technology at the SLAS (Society for Laboratory Automation and Screening) 2020 International Conference & Exhibition at the San Diego Convention Center, Jan. 27-29, 2020.

• StemoniX to Present at Biotech Showcase 2020

  12/19/2019

  StemoniX, Inc., a leader in human microOrgan® platforms for drug discovery and development, announced today that its Co-Founder and Chief Executive Officer Ping Yeh will present at Biotech Showcase 2020, to be held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco.

• StemoniX to Present at Piper Jaffray 31st Annual Healthcare Conference

  11/21/2019

  StemoniX, Inc. announced that its Founder and Chief Executive Officer Ping Yeh and its Chief Financial Officer Andy LaFrence will present at the Piper Jaffray 31st Annual Healthcare Conference, to be held December 3 – 5, 2019 at the Lotte New York Palace in New York.

• StemoniX Appoints Andrew D. C. LaFrence As Chief Financial Officer

  10/16/2019

  StemoniX, Inc., a leader in human microOrgan® platforms for drug discovery and development, today announced the appointment of Andrew (Andy) D. C. LaFrence, CPA, as Chief Financial Officer (CFO)

• StemoniX's microBrain® and microHeart® Platforms to be Featured in Podium Presentation at the PREDiCT: 4th Annual 3D Tissue Models Summit

  9/3/2019

  StemoniX, Inc, a biotech company revolutionizing how new therapeutics are discovered, announced today that its Research and Development Director, Fabian Zanella, Ph.D., will deliver a podium presentation, "Expertise Insight by StemoniX," highlighting the company's microBrain 3D and microHeart technology at the PREDiCT: 4th Annual 3D Tissue Models Summit in Boston, Sept. 4-6, 2019

• StemoniX's microBrain® 3D to be Featured in Podium Presentation at World Pharma Week's 18ᵗʰ Annual World Preclinical Congress

  6/11/2019

  StemoniX's Director, Research and Development, Fabian Zanella, PhD, to present during the "iPS Cells for CNS Drug Discovery and Development" session

• StemoniX® Announces Collaborative Research Agreement with the NIH's National Center for Advancing Translational Sciences (NCATS)

  5/1/2019

  StemoniX® Inc., a biotech company revolutionizing how new medicines are discovered, announced that it entered into a Research Collaboration Agreement with the National Center for Advancing Translational Sciences (NCATS)

• StemoniX® Secures $14.4 Million to Accelerate Commercialization of microOrgan® Drug Discovery Platforms

  2/28/2019

  StemoniX® Inc., a biotech company revolutionizing how new medicines are discovered, announced today that it has secured $14.4 million USD in Series B funding from a group of institutional and private investors

• StemoniX® Uses microBrain® 3D, a Functional In Vitro Human Neural Model, to Identify Potential Treatment Modalities for Rett Syndrome

  2/14/2019

  StemoniX® Inc., a biotech company revolutionizing how new medicines are discovered, announced today that Cassiano Carromeu, PhD, lead neuroscientist at StemoniX, presented research during the SLAS2019 annual meeting demonstrating the ability of microBrain® 3D to produce a functional in vitro disease model for Rett Syndrome (RTT) via human induced Pluripotent Stem Cells (hiPSCs) derived from RTT patients.

• Pairnomix Teams Up With StemoniX To Co-Develop New Epilepsy Model

  7/18/2017

• StemoniX Wins MN Cup Grand Prize, Named Best Breakthrough Business Idea Of 2016

  9/27/2016